ImmunityBio Inc. Stock
€5.29
Your prediction
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | 6.990% | -3.045% | 202.662% | 59.217% | 202.662% | 51.461% | -66.028% |
| Ardelyx Inc. | -0.760% | -1.247% | 32.166% | 23.657% | 32.166% | 152.804% | 2.624% |
| Evolus Inc | -2.050% | -7.282% | -29.908% | -71.704% | -29.908% | -57.318% | -27.487% |
| Champions Oncology Inc | -1.600% | 7.895% | 6.034% | -41.429% | 6.034% | 66.216% | -32.044% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.
Trading
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do